# HOOKIPA Pharma Inc. (HOOK)

Source: https://www.quantisnow.com/company/HOOK
Generated: 2026-11-11T15:47:06.820Z

- Ticker: HOOK
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- SEC CIK: 0001760542
- Website: hookipapharma.com

## About

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

## Latest HOOK news and filings

- 2026-03-26 11:00 UTC [HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics](https://www.quantisnow.com/insight/hookipa-pharma-announces-completion-of-sale-of-oncology-assets-to-6469853)
- 2026-02-03 13:30 UTC [HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics](https://www.quantisnow.com/insight/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics-6371427)
- 2025-10-31 12:00 UTC [HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead](https://www.quantisnow.com/insight/hookipa-pharma-announces-completion-of-sale-of-hbv-and-hiv-6253710)
- 2025-10-09 20:22 UTC [SEC Form 4] [Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-peters-malte-sold-20684-worth-of-shares-6229066)
- 2025-08-08 16:48 UTC [SEC Form 15-12G filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-hookipa-pharma-inc-6155911)
- 2025-07-30 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-hookipa-pharma-inc-6137416)
- 2025-07-30 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-hookipa-pharma-inc-6137415)
- 2025-07-29 20:16 UTC [SEC Form 25 filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-25-filed-by-hookipa-pharma-inc-6136672)
- 2025-07-29 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-hookipa-pharma-inc-6136558)
- 2025-07-29 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-hookipa-pharma-inc-6136547)
- 2025-07-29 20:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-hookipa-pharma-inc-6136537)
- 2025-07-29 20:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-hookipa-pharma-inc-6136533)
- 2025-07-29 20:04 UTC [SEC Form POS AM filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-hookipa-pharma-inc-6136386)
- 2025-07-29 20:04 UTC [SEC Form POS AM filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-hookipa-pharma-inc-6136381)
- 2025-07-29 20:01 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-submission-of-matters-6136354)
- 2025-07-23 22:09 UTC [SEC Form 4] [Chief Executive Officer Peters Malte sold $26,842 worth of shares (29,176 units at $0.92), decreasing direct ownership by 27% to 79,519 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-peters-malte-sold-26842-worth-of-shares-6130264)
- 2025-07-23 22:07 UTC [SEC Form 4] [EVP and CFO Coelho Mary Theresa sold $12,520 worth of shares (13,609 units at $0.92), decreasing direct ownership by 19% to 56,266 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-and-cfo-coelho-mary-theresa-sold-12520-worth-of-6130262)
- 2025-07-18 20:11 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6125486)
- 2025-07-18 20:05 UTC [HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock](https://www.quantisnow.com/insight/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-6125399)
- 2025-07-03 19:04 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-hookipa-pharma-inc-6110703)
- 2025-06-30 21:13 UTC [SEC Form PRER14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-prer14a-filed-by-hookipa-pharma-inc-6104188)
- 2025-06-14 01:45 UTC [SEC Form PREM14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-hookipa-pharma-inc-6086998)
- 2025-06-04 20:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-hookipa-pharma-inc-6072377)
- 2025-05-22 12:03 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-hookipa-pharma-inc-6053597)
- 2025-05-22 12:00 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-entry-into-a-6053587)
- 2025-05-15 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-hookipa-pharma-inc-6041878)
- 2025-04-30 21:03 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-hookipa-pharma-inc-6011224)
- 2025-02-20 21:01 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-other-events-financial-5899969)
- 2025-02-14 21:25 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-hookipa-pharma-inc-5890950)
- 2025-02-14 17:26 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-hookipa-pharma-inc-5889774)
- 2025-01-30 12:00 UTC [HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV](https://www.quantisnow.com/insight/hookipa-pharma-announces-enrollment-completion-of-phase-1b-clinical-trial-5862560)
- 2025-01-29 13:02 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-5860962)
- 2025-01-10 21:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-hookipa-pharma-inc-5841782)
- 2025-01-10 21:00 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-other-events-financial-5841772)
- 2025-01-07 21:05 UTC [HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements](https://www.quantisnow.com/insight/hookipa-pharma-announces-notice-to-shareholders-regarding-uk-disclosure-requirements-5837489)
- 2025-01-07 11:40 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-hookipa-pharma-inc-5836598)
- 2025-01-07 11:35 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-other-events-financial-5836595)
- 2025-01-02 11:05 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by HOOKIPA Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-hookipa-pharma-inc-5828404)
- 2025-01-02 11:00 UTC [SEC Form 8-K] [HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hookipa-pharma-inc-filed-sec-form-8-k-other-events-financial-5828379)
- 2024-12-20 12:37 UTC [Analyst Downgrade] [HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target](https://www.quantisnow.com/insight/hookipa-pharma-downgraded-by-rbc-capital-mkts-with-a-new-5821410)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/HOOK
- Earnings history: https://www.quantisnow.com/earnings/HOOK
- Dividend history: https://www.quantisnow.com/dividends/HOOK
- Insider transactions: https://www.quantisnow.com/insiders/HOOK
- Options chain: https://www.quantisnow.com/options/HOOK
- SEC 8-K filings only: https://www.quantisnow.com/company/HOOK/8-k
- RSS and alerts for HOOK: https://www.quantisnow.com/docs/rss-feeds.md